Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1157]
News [2523]
Articles [155]
Editorials [8]
Conferences [103]
elearning [18]
Oncology pharmacist perspective on PARP inhibitors for castration-resistant...
Dr Grace Martin - The University of Kansas Cancer Center, Kansas City, USA
Oncology pharmacist perspective on PARP inhibitors for castration-resistant prostate cancer ( Dr Grace Martin - The University of Kansas Cancer Center, Kansas City, USA )
27 Jul 2020
The role of PARP-2 in inhibiting prostate cancer
Prof Li Jia - Harvard Medical School, Boston, USA
The role of PARP-2 in inhibiting prostate cancer ( Prof Li Jia - Harvard Medical School, Boston, USA )
27 Jul 2020
KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with...
Prof Scott Tykodi - University of Washington, Seattle, USA
KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with advanced clear cell renal cell carcinoma ( Prof Scott Tykodi - University of Washington, Seattle, USA )
14 Jul 2020
Association of gene expression with clinical outcomes in RCC patients treated...
Prof Scott Tykodi - University of Washington, Seattle, USA
Association of gene expression with clinical outcomes in RCC patients treated with pembrolizumab ( Prof Scott Tykodi - University of Washington, Seattle, USA )
14 Jul 2020
Renal cell cancer: Highlights from ASCO 2020
Prof Scott Tykodi - University of Washington, Seattle, USA
Renal cell cancer: Highlights from ASCO 2020 ( Prof Scott Tykodi - University of Washington, Seattle, USA )
13 Jul 2020
FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment...
Prof Scott Tykodi - University of Washington, Seattle, USA
FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-refractory advanced renal cell carcinoma ( Prof Scott Tykodi - University of Washington, Seattle, USA )
13 Jul 2020
HERO: Relugolix versus leuprolide acetate for advanced prostate cancer
Dr Neal Shore - Carolina Urologic Research Center, South Carolina, USA
HERO: Relugolix versus leuprolide acetate for advanced prostate cancer ( Dr Neal Shore - Carolina Urologic Research Center, South Carolina, USA )
10 Jul 2020
The future of PARP inhibitors in prostate cancer
Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain
The future of PARP inhibitors in prostate cancer ( Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain )
2 Jul 2020
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
30 Jun 2020
ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer
Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany
ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )
24 Jun 2020
FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO...
Prof Robert Huddart and Dr Ignacio Durán
FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2020 ( Prof Robert Huddart and Dr Ignacio Durán )
15 Jun 2020
CTC count as a prognostic marker for androgen deprivation plus orteronel or...
Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA
CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC ( Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA )
12 Jun 2020

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation